Eosinophilic pneumonia induced by ceftaroline

American Journal of Health-System Pharmacy

Volumn 71, Issue 5, 2014, Pages 403-406

  Griffiths, Carrie L ^a,b   Gutierrez, Kristofer C ^c   Pitt, Renee D ^c   Lovel, Roger D ^c  

^a WINGATE UNIVERSITY   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE FOSAMIL; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; VANCOMYCIN; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CEFTAROLINE; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE;

ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALCOHOL ABUSE; ANTIBIOTIC THERAPY; ARTICLE; ASSISTED VENTILATION; BACTERIUM CULTURE; BODY TEMPERATURE; BRONCHOSCOPY; CASE REPORT; CEFTAROLINE INDUCED EOSINOPHILIC PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHIL COUNT; EOSINOPHILIA; ESCHERICHIA COLI INFECTION; FACE FRACTURE; FEMALE; FEVER; HOSPITAL ADMISSION; HUMAN; HYPOXEMIA; HYPOXIA; INTENSIVE CARE UNIT; LEUKOCYTE COUNT; LOEFFLER PNEUMONIA; LUNG INFILTRATE; LUNG LAVAGE; MEDICAL HISTORY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PENICILLIN ALLERGY; PLEURA EFFUSION; SMOKING; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; THORAX RADIOGRAPHY; TOBACCO USE; TRACHEOBRONCHIAL TOILET; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; ANOXIA; CHEMICALLY INDUCED DISORDER; DRUG HYPERSENSITIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PATHOPHYSIOLOGY; STAPHYLOCOCCUS INFECTION;

AGED; ANOXIA; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CEPHALOSPORINS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; METHYLPREDNISOLONE; PENICILLINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EOSINOPHILIA; STAPHYLOCOCCAL INFECTIONS;

EID: 84907205271     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130441     Document Type: Article

References (34)

1. Teflaro (ceftaroline fosamil) package insert. St. Louis: Forest Pharmaceuticals; Oct. Revised 2013 May.
2. Ceftaroline fosamil (Teflaro) - a new iv cephalosporin. Med Lett Drugs Ther. 2011; 53:5-7.
3. Facts and Comparisons. Ceftaroline fosamil monograph. http://online.factsandcomparisons.com/MonoDisp.aspx?monoID=fandc-hcp17871&quick=902990%7c5&search=902990%7c5&isstemmed=True&fromTop=true#first Match (accessed 2013 Jun 15).
4. Lexicomp. Ceftaroline fosamil monograph. https://online.lexi.com/lco/action/doc/retrieve/docid/patch-f/2940159 (accessed 2013 Jun 15).
5. Biek D, Critchley IA, Riccobene TA et al. Ceftaroline fosamil: a novel broad-spectrum cephalosporins with expanded anti-gram-positive activity. J Antimicrob Chemother. 2010; 65(suppl 4): iv9-16.
6. Zainah H, Vazquez JA. Use of ceftaroline in complicated methicillin-resistant Staphylococcus aureus bacteremia. Infect Dis Clin Pract. 2013; 21:58-60.
7. Lin JC, Aung G, Thomas A et al. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013; 19:42-9.
8. Ho TT, Cadena J, Childs LM et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012; 67:1267-70.
9. Goodman JJ, Martin SI. Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections. Ther Clin Risk Manag. 2012; 8:149-56.
10. Meyer KC, Raghu G, Baughman RP et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012; 185:1004-14.
11. Sohn JW. Acute eosinophilic pneumonia. Tuberc Respir Dis. 2013; 74:51-5.
12. Cottin V, Cordier JF. Eosinophilic pneumonias. Allergy. 2005; 60:841-57.
13. Liebow AA, Carrington CB. The eosinophilic pneumonias. Medicine. 1969; 48:251-85.
14. Solomon J, Schwarz M. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. Semin Respir Crit Care Med. 2006; 27:192-7.
15. Lee M. Basic skills in interpreting laboratory data, 4th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2009:347.
16. Elsevier/Gold Standard. Cefdinir monograph. http://clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=688&sec=monadve&t=0 (accessed 2013 Jun 16).
17. Elsevier/Gold Standard. Daptomycin monograph. http://clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=2280&sec=monadve&t=0 (accessed 2013 Jun 16).
18. Smith J, Weinstein V. Drug points: cephalexin associated pulmonary infiltration with circulating eosinophilia. Br Med J. 1987; 294:776.
19. Dreis DF, Winterbauer RH, van Norman GA et al. Cephalosporin-induced interstitial pneumonitis. Chest. 1984; 86:138-40.
20. Irie M, Teshima H, Matsuura T et al. Pulmonary infiltrates with eosinophilia possibly induced by cefotiam in a case of steroid-dependent asthma. Jpn J Thorac Dis. 1990; 28:1353-8.
21. Desai KR, Burdette SD, Polenakovik HM et al. Ceftaroline-induced eosinophilic pneumonia. Pharmacotherapy. 2013; 33:166-9.
22. File TM Jr, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012; 55(suppl 3):S173-80.
23. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011; 66(suppl 3):iii53-9.
24. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010; 65(suppl 4):iv67-71.
25. Allen J. Acute eosinophilic pneumonia. Semin Respir Crit Care Med. 2006; 27:142-7.
26. Allen J. Drug-induced eosinophilic lung disease. Clin Chest Med. 2004; 25:77-88.
27. Jantz MA, Sahn SA. Corticosteroids in acute respiratory failure. Am J Respir Crit Care Med. 1999; 160:1079-100.
28. Wallen N, Kita H, Weiler D et al. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol. 1991; 147:3490-5.
29. Jeong YJ, Kim KI, Seo IJ et al. Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. Radiographics. 2007; 27:617-39.
30. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
31. Campagna JD, Bond MC, Schabelman E, Hayes BD. The use of cephalosporins in penicillin-allergic patients: a literature review. J Emerg Med. 2012; 42:612-20.
32. Hogan SP, Rosenberg HF, Moqbel R et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008; 38:709-50.
33. Olsson I, Venge P. The role of the eosinophil granulocyte in the inflammatory reaction. Allergy. 1979; 34:353-67.
34. Gotlib J. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011; 86:678-88.